Evaluation of the colchicine on the myocardial infarction

Evaluation of the low dose colchicine on the clinical outcome of patient with ST elevation myocardial infarction

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20231001059578N1

Enrollment

180

Registered

2023-10-21

Start date

2023-10-03

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myocardial infarction. ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction

Interventions

Intervention 1: An oral loading dose of 2 mg equivalent to 2 colchicine (from Mofid Pharma Pharmaceutical Company) tablets will be given to the patients, followed by 0.5 mg once a day orally for 30 da

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 18 to 80 years old patient Occurrence of STE in the patient's ECG

Exclusion criteria

Exclusion criteria: Unstable vital signs of patients Known drug sensitivity to colchicine Severe liver and kidney disease Chronic treatment with colchicine

Design outcomes

Primary

Measure	Time frame
The functional class of the patient until the occurrence of chest pain. Timepoint: At the beginning of the study, the first day, when the patients were discharged and after 40 days from intervention. Method of measurement: check list.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli khosrobeigi

Ghoum University of Medical Sciences

ali.khosrobeigi@gmail.com+98 25 3612 2000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026